<DOC>
	<DOCNO>NCT00791232</DOCNO>
	<brief_summary>The purpose study noninferiority comparison orthostatic tolerability dose 12 mg extended-release ( ER ) OROS paliperidone current recommend initial titration dose ( 2 mg ) immediate-release ( IR ) risperidone patient schizophrenia . Other study objective 1 ) compare tolerability safety clinically equivalent fix dose ER OROS paliperidone currently recommend dose risperidone , 2 ) compare early tolerability 2 treatment placebo , 3 ) compare tolerability 2 treatment , use population pharmacokinetic/pharmacodynamic ( pop PK/PD ) model , 4 ) ass relationship genetic variability drug metabolize enzyme interindividual variability plasma exposure paliperidone risperidone within treatment group .</brief_summary>
	<brief_title>A Study Extended Release Extended-release ( ER ) OROS Paliperidone Tolerability , Compared Immediate-release ( IR ) Risperidone , Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize , double-blind , placebo- active-controlled , parallel group , Phase 1 . The study patient schizophrenia consist 1 week , open-label , placebo washout period ( Days -7 -1 ) 6 day double-blind treatment period patient receive 1 3 treatment : placebo Day 1 ER OROS paliperidone ( 12 mg ) Days 2 6 , ER OROS paliperidone ( 12 mg ) Days 1 6 , IR risperidone 2 mg Day 1 4 mg Days 2 6 . Safety tolerability monitor throughout study.. ER OROS paliperidone ( 12 mg , oral ) Days 2 6 , ER OROS paliperidone ( 12 mg , oral ) Days 1 6 , IR risperidone ( oral ) 2 mg Day 1 4 mg Days 2 6</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Willingness spend 2 week inpatient washout treatment period Currently treat oral risperidone antipsychotic monotherapy least 1 month prior screen DSMIV diagnosis schizophrenia ( Patients diagnosis schizophrenia [ paranoid type ( 295.30 ) , disorganize type ( 295.10 ) , catatonic type ( 295.20 ) , undifferentiated type ( 295.90 ) , residual type ( 295.60 ) ] define DSMIV criterion Absence acute exacerbation minimum 6 month prior screen Female patient must postmenopausal least 1 year , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) screen throughout study , negative urine pregnancy test screen baseline The patient otherwise healthy basis physical examination , medical history , electrocardiogram , result blood biochemistry hematology test urinalysis perform within 30 day start treatment period . If result biochemistry hematology test urinalysis test within laboratory 's reference range , patient may include condition investigator judge deviation clinically significant . Involuntarily committed inpatient Patients receive longacting depot antipsychotic medication ( discontinue RISPERDAL CONSTA le 10 week discontinue depot less 2 cycle ) Any significant history cardiovascular disease : atrial fibrillation flutter , second third degree heart block equivalent , rest supraventricular tachycardia ( &gt; 100 beat per minute ) , unstable atherosclerotic heart disease , valvular abnormality Body Mass Index &gt; = 35 kg/m2 history current hypertension Use disallow concomitant therapy patient likely require prohibit concomitant therapy participation study Patients pacemaker Concomitant disease central nervous system would bias study evaluation , e.g . stroke , brain tumor , Parkinson 's disease , significant brain trauma , Alzheimer 's disease , epilepsy , multiple sclerosis , currentlytreated migraine A DSMIV Axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen evaluation ( nicotine caffeine dependence exclusionary ) Diabetes mellitus and/or repeat fast blood glucose value washout period &gt; 126 mg/dl /or HbA1C &gt; 7 . 5 % , hypothalamohypophyse dysfunction , Cushing , Addison , thyrotoxicosis , Anemia ( define hematocrit &lt; 30 % ) Suicidal homicidal ideation Positive drug screen screen baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Extended-release paliperidone</keyword>
	<keyword>Schizophrenia , Mood disorder , Antipsychotic drug</keyword>
	<keyword>ER OROS paliperidone</keyword>
</DOC>